RIOFY
LIVE

Serial Number

99027161

Owner

CMG Pharmaceutical CO., LTD.

Attorney

Hun Joon Kim

Filing Date

Feb 3, 2025

Add to watchlist:

No watchlists yet
View on USPTO

RIOFY Trademark

Serial Number: 99027161

RIOFY is a trademark filed by CMG Pharmaceutical CO., LTD. on February 3, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

CMG Pharmaceutical CO., LTD.

306, 170, Hakdong-ro, Gangnam-gu
Seoul 06112 , KR

Entity Type: 03

Trademark Details

Filing Date

February 3, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, and auto-immune disease; Biotechnological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, and auto-immune disease; Biological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, and auto-immune disease; Medicines for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, and auto-immune disease; Pharmaceuticals for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, and auto-immune disease

Filing History

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
May 6, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
May 6, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
May 6, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 1, 2026 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 26, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 26, 2025 GNSL
SUSPENSION LETTER WRITTEN
Aug 26, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 25, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 25, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 25, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 18, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 18, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 18, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 14, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 3, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 3, 2025 NWOS
NEW APPLICATION ENTERED
Feb 3, 2025 NWAP